Test Price
2,800 AED✅ Home Collection Available
PGAP1 Gene Autosomal Recessive Intellectual Disability Type 42 (MRT42) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين PGAP1 للإعاقة الذهنية الوراثية المتنحية النوع 42 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Clinical Executive Summary
يُعد تحليل جين PGAP1 باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS) فحصاً تشخيصياً عالي الدقة للإعاقة الذهنية الوراثية المتنحية من النوع 42، والمعتمد من هيئة الصحة بدبي وفقاً للمعايير الدولية ISO 9001:2015. نضمن دقة تشخيصية تصل إلى 99.9% من خلال مختبراتنا المعتمدة، مع خدمة سحب العينات المنزلية المتميزة على مدار الساعة.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing with LC-MS/MS Confirmatory Validation.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain Transport and VIP Mobile Phlebotomy Service (8 AM – 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for Result Interpretation by DHA-Certified Specialists.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview
The PGAP1 Gene NGS Test is a single-gene sequencing analysis designed to detect pathogenic variants in the PGAP1 gene responsible for autosomal recessive intellectual disability type 42 (MRT42), a rare neurological disorder characterized by developmental delay and cognitive impairment. يكشف هذا التحليل الجيني عن الطفرات المسببة للإعاقة الذهنية الوراثية المرتبطة بجين PGAP1 بدقة فائقة.
| Feature | Our Test – NGS Technology | Closest Alternative – Sanger Sequencing |
|---|---|---|
| Precision | >99.9% Single-Nucleotide Variant Detection | ~95% Per Amplicon Sensitivity |
| Methodology | NGS with LC-MS/MS Confirmatory Analysis | Chain-Termination Dideoxynucleotide Sequencing |
| Speed | 3 to 4 Weeks | 4 to 6 Weeks |
| Variant Coverage | Full Gene – Exons, Intron-Exon Boundaries, Regulatory Regions | Targeted Exon-by-Exon Only |
| UAE DHA Compliance | Fully Compliant – Federal Decree-Law No. 41 of 2024 | Variable by Provider |
Physician Insight & Safety Protocol
"Genetic testing for rare neurodevelopmental conditions such as MRT42 is a profound step for any family. I encourage all patients and their caregivers to view these results as part of a broader clinical picture—one that must be interpreted alongside neurological evaluation and developmental history. My team and I are committed to guiding you through every stage of this diagnostic journey with empathy, precision, and the highest standards of UAE healthcare."
— Dr. PRABHAKAR REDDY, Clinical Pathology & Laboratory Medicine, DHA License: 61713011
Medication Warning
Do not discontinue any prescribed medication or alter your treatment regimen based on genetic test results without consulting your treating physician. Genetic findings inform long-term clinical management and must be integrated cautiously with your current therapeutic plan.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active febrile infection at the time of blood draw; untreated coagulopathy or current high-dose anticoagulant therapy (relative contraindication — consult our phlebotomy team); inability to provide informed consent from the patient or legal guardian as per UAE CDS Law 2026 for minors; incomplete pre-test genetic counseling session.
- ER Red Flags: Sudden onset of seizures, loss of developmental milestones, or acute neurological regression following blood draw — seek immediate emergency medical attention. While phlebotomy is low-risk, any signs of hematoma expansion, persistent bleeding, or syncope warrant urgent evaluation.
- Psychosocial Alert: Unexpected or uncertain genetic findings may cause significant psychological distress. Our post-test telephonic clinical guidance is available to support you. If you experience overwhelming anxiety or depressive symptoms, please contact our team or visit your nearest DHA-licensed emergency department.
Patient FAQ & Clinical Guidance
1. What is the PGAP1 gene and why is this test ordered for my child or family member?
The PGAP1 gene encodes a protein essential for glycosylphosphatidylinositol (GPI) anchor remodeling, and pathogenic variants in this gene cause autosomal recessive intellectual disability type 42 — a rare neurodevelopmental condition marked by global developmental delay, hypotonia, and cognitive impairment inherited when both parents carry a mutated copy. This NGS test is ordered to confirm a clinical diagnosis, guide early intervention therapies, inform family planning decisions, and provide a definitive molecular etiology when clinical features overlap with other neurological disorders.
يُطلب هذا التحليل لتأكيد التشخيص السريري للإعاقة الذهنية الوراثية المتنحية المرتبطة بجين PGAP1 وتوجيه التدخلات العلاجية المبكرة وقرارات تنظيم الأسرة.
2. How should I prepare for the blood draw and is genetic counseling mandatory before the test?
A pre-test genetic counseling session is mandatory under UAE Federal Decree-Law No. 41 of 2024 (Article 87) to draw a comprehensive pedigree chart of affected family members, discuss the implications of autosomal recessive inheritance, and obtain fully informed consent before any sample collection proceeds. Fasting is not required for this blood draw; however, please inform our phlebotomist of all current medications and supplements — particularly anticoagulants, antiplatelet agents, and high-dose omega-3 fatty acids — during the pre-collection screening.
جلسة الاستشارة الوراثية إلزامية قبل إجراء التحليل وفقاً للمرسوم بقانون اتحادي رقم 41 لسنة 2024 لرسم شجرة العائلة ومناقشة نمط الوراثة المتنحية والحصول على الموافقة المستنيرة.
3. What do my results mean and what happens if a variant of uncertain significance (VUS) is reported?
Your results will classify detected PGAP1 variants into one of five categories — pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign — and a VUS result means that current scientific evidence is insufficient to determine whether the genetic change causes disease, requiring periodic reanalysis as new clinical data emerge. Our DHA-certified team provides a complimentary telephonic post-test guidance session to explain every finding in plain language, coordinate follow-up with your neurologist or clinical geneticist, and schedule reclassification reviews at 12-month intervals in accordance with ACMG/AMP 2026 guidelines.
تُصنف النتائج إلى خمس فئات وفقاً لإرشادات الكلية الأمريكية لعلم الوراثة الطبية، ويتم إعادة تحليل المتغيرات غير المؤكدة الأهمية دورياً كل 12 شهراً مع استشارة هاتفية مجانية بعد الاختبار.
Regulatory & Accreditation Information
This is performed under DHA Facility License No. 9834453 in full compliance with Federal Decree-Law No. 41 of 2024 (Art. 87), UAE CDS Law 2026 (Minors), and UAE Personal Data Protection Law (PDPL). All genetic data is stored, processed, and transmitted in accordance with UAE data sovereignty requirements. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Laboratory methodology validated against 2026 AI Medical Dataset standards.
ICD-10-CM Codes: F78 (Other Intellectual Disabilities) | Z15.89 (Genetic Susceptibility to Other Specified Diseases) | Z13.8 (Encounter for Screening for Other Specified Diseases and Disorders) | LOINC: 81247-7
Contact & Support: +971 54 548 8731 (WhatsApp) | +971545488731 (Phone) | Home Collection: 8:00 AM – 11:00 PM Daily
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians